#USA #Class Action #San Francisco #Hagens Berman #ADMA Biologics

Overview of ADMA Biologics, Inc. Class Action Lawsuit

On July 31, 2026, Hagens Berman Sobol Shapiro LLP announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), highlighting potential securities fraud. This development has raised significant concerns regarding the company's financial integrity, drawing attention from investors and legal professionals alike.

Key Allegations

The lawsuit essentially revolves around allegations that ADMA Biologics made several misrepresentations regarding its financial health, improper revenue recognition, and dubious business practices. Specifically, the suit accuses the company of:

• - Engaging in undisclosed related party transactions.
• - Utilizing channel stuffing tactics to artificially inflate revenue.
• - Lacking adequate internal controls over its reporting and operations.

As a culmination of these acts, the lawsuit claims that the defendants' public statements regarding ADMA Biologics were fundamentally misleading, misleading investors about the company's operational conditions and future prospects.

Timeline of Events

The class period for this lawsuit is set between August 9, 2024, and March 25, 2026. A crucial point came on March 24, 2026, when Culper Research published a short-seller report exposing alleged manipulative practices, including channel stuffing and undisclosed relationships with distributors like Genesis BioPharma. Following these revelations, ADMA’s stock price faced a severe backlash, losing roughly 31.6% over a two-day trading period.

March 26 saw further declines as ADMA issued a response to the short-seller claims, stating it was reviewing the allegations. This move was met with skepticism, especially as analyst ratings reduced further investor confidence, resulting in a further price drop of 13.9%.

The Aftermath and Ongoing Investigation

In light of these events, Hagens Berman has commenced an investigation to determine the extent of the alleged misrepresentations by ADMA Biologics. The firm is particularly seeking information from investors who have sustained losses due to the actions taken by the company.

Reed Kathrein, a partner at Hagens Berman, emphasized the importance of assessing whether ADMA Biologics' statements were misleading and concealed the realities surrounding its financial practices. The firm is committed to advocating for the rights of investors negatively impacted by corporate misconduct.

What Can Affected Investors Do?

Investors who believe they have suffered losses as a result of these alleged actions by ADMA Biologics are encouraged to reach out to Hagens Berman. Those who possess information that could support the investigation or who have suffered notable losses should consider providing that information to assist in the ongoing litigation.

Whistleblowers with knowledge of non-public information related to ADMA are particularly encouraged to contact the firm or utilize the SEC’s Whistleblower program, which awards individuals who provide original information that leads to successful SEC recoveries.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a prominent plaintiffs' rights law firm with a strong focus on complex litigation and corporate accountability. The firm has achieved over $2.9 billion for its clients in a variety of legal matters and continues to operate with the mission of serving those harmed through corporate negligence. For updates and further information, visit their website or follow them on social media platforms.

For those impacted by this situation, it is crucial to stay informed about the developments of this case, seek advice if necessary, and consider the avenues available for retribution against any perceived wrongdoing by ADMA Biologics.